{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:25:30Z","timestamp":1787757930604,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Mucormycosis (MCR) has been increasingly described in patients with coronavirus disease 2019 (COVID-19), but the epidemiological factors, neurological presentation, and outcome of such patients are not well described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To study the patient demographics, presenting symptoms and signs, the role of co-morbidities, medications used to treat COVID-19, and the outcomes of management and to study the spectrum of neuraxis involvement and its outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>It was a prospective, observational, cross-sectional hospital-based single center cohort study. Confirmed MCR cases with and without COVID-19 were collected. The study was carried out over a period of 3 months from May to July 2021, followed by 3-month follow-up. Information on epidemiological factors, neurological findings, treatment (including medical and surgical treatment), and outcome was recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 141 patients were diagnosed with MCR, out of which 98 were COVID-associated MCR (CAM). The CAM incidence was 0.39% among COVID-19-positive patients. The MCR case fatality rate at 90 days was 43.9% but was higher for CAM than for non-CAM patients. Older ages (&gt;50 years), diabetes mellitus, multiple risk factors, diabetic ketoacidosis on admission, brain involvement, and history of COVID-19 pneumonitis were associated with a higher risk for death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Possibly because of improper usage of corticosteroids, zinc, oxygen, and tocilizumab, there was sudden surge of cases of MCR in the COVID-19 pandemic. Therefore, treating physicians should use the COVID-19 pneumonia regimen judiciously. Neurological involvement itself is a poor prognostic sign, but combined surgical and medical management exhibited better outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_1097_21","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T02:29:43Z","timestamp":1654741783000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Covid-19 and Mucormycosis Superinfection"],"prefix":"10.4103","volume":"25","author":[{"given":"Shubham","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Masheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Sardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20240828","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"R2-22-20240828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2009.02972.x","article-title":"The ecology of the Zygomycetes and its impact on environmental exposure","volume":"15","author":"Richardson","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"R3-22-20240828","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: A review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R4-22-20240828","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/mmy\/myy060","article-title":"A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment","volume":"57","author":"Prakash","year":"2019","journal-title":"Med Mycol"},{"key":"R5-22-20240828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-0691.2006.01604.x","article-title":"Mucormycosis: An emerging disease?","volume":"12","author":"Bouza","year":"2006","journal-title":"Clin Microbio Infect"},{"key":"R6-22-20240828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/cir886","article-title":"Future directions in mucormycosis research","volume":"54","author":"Kontoyiannis","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R7-22-20240828","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/mmy\/myu086","article-title":"A prospective study of mucormycosis in North India: Experience from a tertiary care hospital","volume":"53","author":"Bala","year":"2015","journal-title":"Med Mycol"},{"key":"R8-22-20240828","first-page":"1631","article-title":"Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA)","volume":"224","author":"Lamoth","year":"2021","journal-title":"J Infect Dis"},{"key":"R9-22-20240828","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1164\/rccm.202009-3400OC","article-title":"Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU","volume":"203","author":"Fekkar","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R10-22-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11046-021-00528-2","article-title":"Coronavirus disease (Covid-19) Associated Mucormycosis (CAM): Case report and systematic review of literature","volume":"186","author":"Garg","year":"2021","journal-title":"Mycopathologia"},{"key":"R11-22-20240828","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: An Update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi"},{"key":"R12-22-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi"},{"key":"R13-22-20240828","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"key":"R14-22-20240828","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/jof7040298","article-title":"When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis","volume":"7","author":"John","year":"2021","journal-title":"J Fungi (Basel"},{"key":"R15-22-20240828","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMc2018688","article-title":"New-onset diabetes in Covid-19","volume":"383","author":"Rubino","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-22-20240828","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management, and outcomes of mucormycosis in India","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R18-22-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R19-22-20240828","doi-asserted-by":"crossref","first-page":"e140491","DOI":"10.1172\/JCI140491","article-title":"Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection","volume":"131","author":"Files","year":"2021","journal-title":"J Clin Invest"},{"key":"R20-22-20240828","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/blood-2011-07-366526","article-title":"Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients","volume":"118","author":"Potenza","year":"2011","journal-title":"Blood"},{"key":"R21-22-20240828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jof3030048","article-title":"Innate and adaptive immunity to mucorales","volume":"3","author":"Ghuman","year":"2017","journal-title":"J Fungi (Basel"},{"key":"R22-22-20240828","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10654-020-00698-1","article-title":"Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications","volume":"35","author":"Levin","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"R23-22-20240828","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/jof6040305","article-title":"Zinc at the Host\u2013Fungus interface: How to uptake the metal.?","volume":"6","author":"Soares","year":"2020","journal-title":"J Fungi"},{"key":"R24-22-20240828","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijid.2021.08.037","article-title":"Risk factors associated with mucormycosis epidemic during the covid-19 pandemic","volume":"111","author":"Bhanuprasad","year":"2021","journal-title":"Int J Infect Diseases"},{"key":"R25-22-20240828","doi-asserted-by":"crossref","first-page":"102564","DOI":"10.1016\/j.autrev.2020.102564","article-title":"Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: An increased risk for candidemia?","volume":"19","author":"Antinori","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R26-22-20240828","doi-asserted-by":"crossref","first-page":"102267","DOI":"10.1016\/j.dsx.2021.102267","article-title":"COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study from Eastern India, with special emphasis on neurological spectrum","volume":"15","author":"Dubey","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"R27-22-20240828","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0030-6665(00)80010-9","article-title":"Mucormycosis of the nose and paranasal sinuses","volume":"33","author":"Ferguson","year":"2000","journal-title":"Otolaryngol Clin North Am"},{"key":"R28-22-20240828","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.4103\/ijo.IJO_1565_21","article-title":"Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India \u2013 Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1","volume":"69","author":"Sen","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R29-22-20240828","doi-asserted-by":"crossref","first-page":"e044640","DOI":"10.1136\/bmjopen-2020-044640","article-title":"Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies","volume":"11","author":"Pijls","year":"2021","journal-title":"BMJ Open"},{"key":"R30-22-20240828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_1097_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:58:58Z","timestamp":1787756338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_1097_21"}},"subtitle":["Prospective, Obsevational Study in a Single Center"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_1097_21","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}